HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Anixa Biosciences (NASDAQ:ANIX) and maintained a $12 price target.
February 13, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences receives a reiterated Buy rating and a maintained $12 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Anixa Biosciences. This endorsement reaffirms the firm's confidence in ANIX's potential, likely encouraging both current and potential investors about the stock's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100